A putative class-action suit in New Jersey’s federal court accuses the maker of a cancer-treatment drug of cornering the oncology clinic market with an anti-competitive tying arrangement and pricing scheme.

According to the suit, Amgen Inc. of Thousand Oaks, Calif., requires oncology clinics to buy Aranesp, a red blood cell stimulant, if they want better prices for the company’s two white blood cell stimulants, Neulasta and Neupogen. The two drugs hold 98 percent of the market in sales to oncology clinics.